These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33125391)

  • 1. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
    Hässler S; Bachelet D; Duhaze J; Szely N; Gleizes A; Hacein-Bey Abina S; Aktas O; Auer M; Avouac J; Birchler M; Bouhnik Y; Brocq O; Buck-Martin D; Cadiot G; Carbonnel F; Chowers Y; Comabella M; Derfuss T; De Vries N; Donnellan N; Doukani A; Guger M; Hartung HP; Kubala Havrdova E; Hemmer B; Huizinga T; Ingenhoven K; Hyldgaard-Jensen PE; Jury EC; Khalil M; Kieseier B; Laurén A; Lindberg R; Loercher A; Maggi E; Manson J; Mauri C; Mohand Oumoussa B; Montalban X; Nachury M; Nytrova P; Richez C; Ryner M; Sellebjerg F; Sievers C; Sikkema D; Soubrier M; Tourdot S; Trang C; Vultaggio A; Warnke C; Spindeldreher S; Dönnes P; Hickling TP; Hincelin Mery A; Allez M; Deisenhammer F; Fogdell-Hahn A; Mariette X; Pallardy M; Broët P;
    PLoS Med; 2020 Oct; 17(10):e1003348. PubMed ID: 33125391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
    Sazonovs A; Kennedy NA; Moutsianas L; Heap GA; Rice DL; Reppell M; Bewshea CM; Chanchlani N; Walker GJ; Perry MH; McDonald TJ; Lees CW; Cummings JRF; Parkes M; Mansfield JC; Irving PM; Barrett JC; McGovern D; Goodhand JR; Anderson CA; Ahmad T;
    Gastroenterology; 2020 Jan; 158(1):189-199. PubMed ID: 31600487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
    JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
    Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
    Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
    Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
    Aliment Pharmacol Ther; 2019 Aug; 50(3):289-294. PubMed ID: 31267570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.
    Pascual-Oliver A; Casas-Deza D; Cuarán C; García-López S; Corsino-Roche P; Sierra-Moros E; Olier-Martínez P; González-Tarancón R; Vicente-Lidón R
    Inflamm Bowel Dis; 2024 Jun; 30(6):922-929. PubMed ID: 37462462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.
    Maid PJ; Xavier R; Real RM; Pedersen R; Shen Q; Marshall L; Solano G; Borlenghi CE; Hidalgo RP
    J Clin Rheumatol; 2018 Jun; 24(4):177-182. PubMed ID: 29232322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A
    Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
    Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the influence of Fc-γ receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients.
    Mahmoud I; Moalla M; Ben Tekaya A; Charfi R; Rouached L; Bouden S; Tekaya R; Saidane O; Abdelmoula L; Sfar I
    Br J Clin Pharmacol; 2023 Jun; 89(6):1834-1843. PubMed ID: 36609675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
    Andlauer TFM; Link J; Martin D; Ryner M; Hermanrud C; Grummel V; Auer M; Hegen H; Aly L; Gasperi C; Knier B; Müller-Myhsok B; Jensen PEH; Sellebjerg F; Kockum I; Olsson T; Pallardy M; Spindeldreher S; Deisenhammer F; Fogdell-Hahn A; Hemmer B;
    BMC Med; 2020 Nov; 18(1):298. PubMed ID: 33143745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
    Liao TL; Chen YM; Liu HJ; Chen DY
    BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
    Han M; Jung YS; Cheon JH; Park S
    Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.
    Hernández-Breijo B; Navarro-Compán V; Plasencia-Rodríguez C; Parodis I; Gehin JE; Martínez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
    Sci Rep; 2021 Jun; 11(1):11632. PubMed ID: 34079038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing face of septic arthritis complicating rheumatoid arthritis in the era of biotherapies. Retrospective single-center study over 35years.
    Dubost JJ; Pereira B; Tournadre A; Tatar Z; Couderc M; Soubrier M
    Joint Bone Spine; 2017 Jan; 84(1):47-50. PubMed ID: 27269649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease.
    Navajas Hernández P; Mouhtar El Halabi S; González Parra AC; Valdés Delgado T; Maldonado Pérez B; Castro Laria L; Charpentier C; Argüelles-Arias F
    Therap Adv Gastroenterol; 2024; 17():17562848241278145. PubMed ID: 39421002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-DQA1*05 Associates with Extensive Ulcerative Colitis at Diagnosis: An Observational Study in Children.
    Nowak JK; Glapa-Nowak A; Banaszkiewicz A; Iwańczak B; Kwiecień J; Szaflarska-Popławska A; Grzybowska-Chlebowczyk U; Osiecki M; Kierkuś J; Hołubiec M; Chanaj-Kaczmarek J; Radzikowski A; Walkowiak J
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.